Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

News · July 09, 2024

EAN 2024: Eculizumab, Efgartigimod Both Effective for Treatment of Generalized Myasthenia Gravis

However, real-world data show greater reduction in Quantitative Myasthenia Gravis score and higher treatment retention rate with eculizumab

PracticeUpdate Editorial Team


Further Reading